Resources

Sub-Saharan Africa has made remarkable progress, yet approximately 490 mothers and more than 7,500 children under five years still die every day.As global health funding decreases, protecting decades of progress and continuing to build toward a healthier future will require tackling persistent bottlenecks, strengthening civil society advocacy, and coordinating leadership across sectors. What is needed now is bold, sustained political will to ensure every mother, newborn, and child survives and thrives.This published MNCH advocacy resource includes a Sub-Saharan Africa overview brief and country-specific briefs for Zambia, Uganda, Ethiopia, and Tanzania. Together, they outline key calls to action policymakers, funders, and advocates to accelerate the progress needed to improve health outcomes for mothers and children.

In this webinar, researchers from Burkina Faso and Mozambique shared learnings on how country-tailored interventions have helped increase the uptake of the malaria vaccine.As part of Gavi’s Malaria Vaccine Learning Agenda, experts presented findings and lessons learned from the rollout of malaria vaccines in Mozambique and Burkina Faso, sharing strategies to increase uptake through routine immunization platforms. This was the first in a quarterly series this year on learnings from malaria vaccine rollout in Africa.The session was co-moderated by Eleonora Genovese, Senior Programme Manager, Vaccine Programmes, Gavi, the Vaccine Alliance, and Saira Nawaz, Project Director, Primary Health Care, PATH. Featured speakers included Dr. Ali Sie, Centre de Recherche en Santé de Nouna (CRSN), Burkina Faso, and Daan Velthausz, Director, Maraxis BV, Mozambique.

Le cancer du col de l'utérus est le deuxième cancer le plus répandu chez les femmes en Éthiopie, avec plus de 8 000 nouveaux cas estimés en 2022. Afin de contribuer à prévenir de nouveaux cas, l'Éthiopie a introduit le vaccin contre le papillomavirus humain (HPV) en 2018. Conformément à la recommandation de l'Organisation mondiale de la santé (OMS), fondée sur des données démontrant une efficacité et une durée de protection comparables entre un schéma vaccinal à dose unique et un schéma à doses multiples, le pays est passé à un schéma à dose unique en 2024 et a mené une campagne de vaccination multi-âges (CMA) ciblant les filles âgées de 9 à 14 ans. Cette note résume les conclusions d'une étude menée par PATH en collaboration avec le ministère fédéral de la Santé sur le coût et le contexte opérationnel de l'administration du vaccin contre le HPV pendant la campagne CMA.

This brief outlines the current state of health research and development (R&D) financing in Africa and underscores the importance of sustained, country-led investment amid declining global funding. Following a temporary surge during the COVID-19 pandemic, global health R&D financing has contracted significantly. In this context, the analysis frames domestic investment and governance of health R&D as contributors to health security and sovereignty, enabling countries to set national and regional priorities. Where predictable, country-led funding is absent, R&D pathways become fragmented, slowing product development and delaying patient access to lifesaving innovations.Against this backdrop, the brief highlights the need for more coordinated and resilient approaches to financing health R&D in Africa. Drawing on discussions co-hosted by PATH and Impact Global Health, it points to strong evidence that investment in health R&D generates substantial societal and economic returns, strengthens pandemic preparedness, and supports the development of local manufacturing capacity. The recommended actions collectively aim at building sustainable, Africa-led health R&D ecosystems.

Cervical cancer is the second most common cancer among women in Ethiopia, with more than 8,000 new cases estimated in 2022. To help prevent future cases, Ethiopia introduced human papillomavirus (HPV) vaccine in 2018. Following the World Health Organization (WHO) recommendation, based on evidence of comparable efficacy and duration of protection of a single-dose HPV vaccine regimen as multiple doses, the country transitioned to a single‑dose regimen in 2024 and carried out a multi‑age cohort (MAC) campaign targeting girls aged 9 to 14 years. This brief summarizes findings from a study conducted by PATH in collaboration with the Federal Ministry of Health on the cost and operational context of HPV vaccine delivery during the MAC campaign.